Developer docs
API playgroundTry for free, no card

Search company profiles

Touchlight Genetics

Full company profile

uuid0000s8b

Namestring
Touchlight Genetics
Legal namestring
Touchlight Genetics Ltd.
Websiteurl
touchlight.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Touchlight Genetics is a UK-based contract development and manufacturing organization (CDMO) that has built a proprietary cell-free DNA production platform to serve the genetic medicines industry. Founded in 2007 and headquartered in Hampton (London), the company's core technology uses enzymatic rolling circle amplification to produce dbDNA (doggybone DNA) — a minimal, linear, double-stranded, covalently closed DNA vector — eliminating the bacterial fermentation step required by traditional plasmid DNA (pDNA) manufacture. This approach reduces production timelines from months to 5-6 weeks, removes antibiotic resistance genes and bacterial sequences from the final product, and operates at a fraction of the facility footprint of conventional CDMOs. The portfolio has expanded to include z-dbDNA (optimized for mRNA production) and mbDNA (a circular single-stranded DNA platform for non-viral gene editing).

Touchlight monetizes through three primary revenue streams: (1) tiered custom DNA manufacturing services spanning Discovery (<1mg, RUO), R&D (2.5mg-5g, RUO), SMart GMP (75mg-5g), and full GMP scales; (2) technology licensing to pharmaceutical partners — including Pfizer, GSK, and Voyager — generating upfront payments, development and commercial milestones, and royalties; and (3) catalogue product and kit sales, including the EnClose Cell-free dbDNA Synthesis Kit co-developed with New England Biolabs. Customers span biotech and pharma companies developing mRNA vaccines, AAV and lentiviral vectors, gene editing therapies, DNA vaccines, and non-viral gene therapies. Distribution extends through channel partnerships with Lonza and Curia for mRNA manufacturing integration.

The Morelands facility in Hampton — a converted Victorian waterworks — is the world's largest cell-free DNA manufacturing site, with 15 production suites and capacity of up to 1kg GMP DNA per month. Touchlight holds the first FDA Drug Master File for an enzymatic DNA platform (2022) and the world's first MHRA GMP license for cell-free DNA manufacturing (January 2025). Nine clinical-stage programs and 8+ IND/CTA filings reference dbDNA, with expansion underway into animal health (Ceva partnership, January 2025), aquaculture (Touchlight Aquaculture spin-off, 2020), and defense applications (DSTL/Naval Research biobattery grants).

Short descriptiontext

Touchlight Genetics is a UK-based CDMO operating a proprietary cell-free enzymatic DNA manufacturing platform (dbDNA) that supplies GMP-grade synthetic DNA to biotech and pharmaceutical companies developing mRNA vaccines, viral vectors, gene editing therapies, and DNA vaccines.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersHampton, United Kingdom
HQ citystring
Hampton
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell-free DNA manufacturing, CDMO services, enzymatic DNA synthesis, genetic medicine manufacturing, DNA vaccine production
Industry5 codes
PRIMARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Contract DNA Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Development and Manufacturing (CDMO) Services
TypeProfessional Services
Description

Touchlight operates as a CDMO providing custom DNA manufacturing services at multiple scales (Discovery, R&D, SMart GMP, GMP) using its proprietary cell-free dbDNA technology. Revenue is earned through service contracts with biotech and pharma clients who require GMP or RUO-grade DNA for their genetic medicine programs. The company supplies DNA as a critical starting material or raw material for mRNA vaccines, viral vectors (AAV, lentivirus), gene therapies, and DNA vaccines. Customers include pharmaceutical companies, biotech firms, and academic institutions.

touchlight.com
2Technology Licensing
TypeLicensing Royalties
Description

Touchlight licenses its enzymatic DNA technology (dbDNA patent portfolio) to pharmaceutical companies for use in their own manufacturing processes. Licensing agreements include upfront payments, development and commercial milestone payments, and royalties upon commercialisation. Notable licensees include Pfizer (for mRNA vaccines and gene therapies), GSK (for mRNA manufacturing), and Voyager (for capsid discovery platform).

touchlight.com
3Catalogue Products
TypeOne Time License
Description

Touchlight sells catalogue DNA products including NVGT (CMV/NVGT Reporters), lentivirus, AAV, gene editing HDR templates, and mRNA constructs for research use.

touchlight.com
4Kit Sales (Collaboration with NEB)
TypeTransaction Fee
Description

Touchlight co-developed and commercialises the EnClose Cell-free dbDNA Synthesis Kit with New England Biolabs (NEB), providing researchers access to Touchlight's enzymatic DNA synthesis technology in kit format for accelerated DNA and RNA therapeutic development.

prnewswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details4 tiers
1Discovery Scale: RUO grade DNA up to 1mg for early-stage research
ModelOtherBilling cadenceMulti-year contract
Notes

Research Use Only (RUO) grade, up to 1mg deliverable. Used for early-stage genetic innovation.

touchlight.com
2R&D Scale: RUO grade up to 5g for research and development
ModelOtherBilling cadenceMulti-year contract
Notes

Research Use Only (RUO) grade, scalable from 2.5mg to 5g for innovation development.

touchlight.com
3SMart GMP Scale: Accelerating GMP readiness (75mg-5g)
ModelOtherBilling cadenceMulti-year contract
Notes

Designed to accelerate GMP readiness with scalable DNA solutions, bridging R&D and full GMP.

touchlight.com
4GMP Scale: High-purity GMP DNA manufacturing (75mg-5g)
ModelOtherBilling cadenceMulti-year contract
Notes

GMP-certified manufacturing for advanced therapies. First cell-free DNA GMP license globally from MHRA (2025).

touchlight.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1dbDNA™ (doggybone DNA)
Description

Enzymatically manufactured double-stranded DNA vector technology for genetic medicines including mRNA, AAV, gene editing, and non-viral therapies

touchlight.com
+3 more records
Core offering1 text field

Touchlight Genetics is a contract development and manufacturing organization (CDMO) that produces high-purity, cell-free DNA using proprietary enzymatic rolling circle amplification (RCA) technology. The company manufactures dbDNA, z-dbDNA, and mbDNA at multiple scales (Discovery, R&D, SMart GMP, and full GMP) for use as starting material in mRNA vaccines, AAV and lentiviral vectors, gene editing, DNA vaccines, and non-viral gene therapies. The company also licenses its enzymatic DNA patent portfolio to major pharmaceutical companies including Pfizer, GSK, and Voyager.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • GMP-grade dbDNA deliverable in 5-6 weeks, vs. months for traditional plasmid DNA manufacturing
+6 more records
Product overview1 text field

Touchlight Genetics is a pioneering CDMO offering cell-free DNA manufacturing technologies for genetic medicines. The company's core technology portfolio consists of three proprietary DNA platforms: dbDNA (doggybone DNA) - the foundational linear double-stranded DNA vector, z-dbDNA - an optimized variant for mRNA production, and mbDNA (MegaBulb DNA) - a circular single-stranded DNA platform for gene editing. These platforms are delivered through tiered manufacturing services spanning Discovery Scale (RUO, <1mg), R&D Scale (RUO, 2.5mg-5g), SMart GMP (75mg-5g), and full GMP Scale manufacturing. The technology supports a broad range of applications including mRNA synthesis, AAV vector production, lentiviral vector manufacturing, gene editing, DNA vaccines, and non-viral gene therapy. Touchlight's enzymatic cell-free manufacturing eliminates traditional bacterial fermentation, enabling faster production timelines, higher purity, and scalability without antibiotic resistance genes.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1U.S. Office for Naval Research / UK Defence Science & Technology Laboratory
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-17
Description

Touchlight was awarded a grant extension (second grant) from the U.S. Office for Naval Research and UK Defence Science & Technology Laboratory (DSTL) to further develop DNA-enabled biobatteries, expanding Touchlight's DNA technology applications beyond biomedical uses.

touchlight.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-17
Description

Touchlight announced a strategic partnership with SVF Vaccines to progress SVF's innovative Hepatitis B/D vaccine into clinical development using Touchlight's dbDNA technology as the DNA starting material.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-18
Description

New England Biolabs and Touchlight collaborated to develop and release the EnClose Cell-free dbDNA Synthesis Kit, enabling rapid, cell-free DNA synthesis for therapeutics development. The kit offers a scalable and regulatory-friendly alternative to traditional plasmid DNA manufacturing, supporting gene and mRNA therapies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-16
Description

Ceva Animal Health (5th largest global animal health company) entered into a broad-ranging agreement with Touchlight for the development and manufacture of new dbDNA vaccines and therapeutics across a wide range of animal health indications. The agreement includes upfront payment, development milestones, and royalties on commercialised products. Dr Ian Thompson leads the collaboration. Stonehaven Transactions acted as strategic adviser to Touchlight.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-07-23
Description

GSK signed a license agreement for use of Touchlight's enzymatic dbDNA production technology for mRNA manufacturing. The agreement enables GSK access to the technology for rapid production of DNA template as starting material for mRNA-based vaccines, therapeutics, and gene therapies.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-07-02
Description

Touchlight and LenioBio collaborate to accelerate development of protein therapeutics for pandemic response, as part of LenioBio's CEPI grant. Touchlight contributes its enzymatic dbDNA to the collaborative programme.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-05-09
Description

Touchlight Genetics and the UK's National Physical Laboratory (NPL) were jointly awarded a grant to develop a novel gene-length single-stranded genome editing template, advancing the application of Touchlight's DNA technology in precision gene editing.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-03-28
Description

Touchlight was awarded a tender to supply enzymatic dbDNA to CPI's RNA Centre of Excellence, supporting the development and manufacturing of RNA therapeutics through access to Touchlight's cell-free DNA technology.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-07-24
Description

Curia expanded its biologics capabilities with access to Touchlight's doggybone DNA to complement its mRNA manufacturing offering, enabling Curia's customers to access Touchlight's enzymatic DNA technology.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-04-18
Description

Touchlight and 20Med Therapeutics are collaborating to establish a novel vaccination platform combining Touchlight's rapid enzymatic dbDNA with 20Med's bioresponsive polymer nanoparticle technology. Preclinical data has shown strong neutralising antibodies and durable T cell responses. Funded in part by the Bill & Melinda Gates Foundation for pandemic preparedness.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-11-15
Description

Voyager Therapeutics signed a license agreement to use Touchlight's DNA technology in Voyager's capsid discovery platform, leveraging dbDNA's rapid, scalable production for AAV capsid development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-06
Description

Lonza integrated Touchlight's dbDNA as an additional, differentiated source of DNA raw material within its end-to-end mRNA manufacturing offering. Customers of Lonza's mRNA manufacturing services gain seamless access to Touchlight's enzymatic DNA technology. The collaboration extends Lonza's offering beyond traditional plasmid DNA while enabling Touchlight to reach customers through Lonza's global mRNA manufacturing network.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-07-06
Description

Pfizer and Touchlight entered into a non-exclusive patent license agreement granting Pfizer worldwide rights to Touchlight's enzymatic dbDNA patent portfolio for use in Pfizer's clinical and commercial manufacture of mRNA-based vaccines, therapeutics, and gene therapies. Touchlight receives an upfront payment, clinical and commercial milestone payments, and royalties upon commercialisation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-08
Description

AskBio and Touchlight restructured their former Touchlight AAV joint venture on 1 February 2022. Both parties benefit from co-exclusive rights to independently supply the AAV market with dbDNA through their respective CDMOs. AskBio owns 100% of the San Sebastian manufacturing site (operated by TAAV) and Touchlight regains co-exclusive rights to manufacture and sell dbDNA for AAV production.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Aldevron is the leading plasmid DNA CDMO serving gene therapy and mRNA developers. It is the closest direct competitor to Touchlight, providing similar custom DNA manufacturing services for AAV, mRNA, and gene editing applications, though via traditional E. coli fermentation.

TypeDirect peer
Description

TriLink is a direct competitor in nucleic acid manufacturing, producing mRNA, plasmid DNA, and clean cap reagents for vaccine and therapeutic developers. They serve overlapping customers in mRNA and gene therapy manufacturing with comparable CDMO service tiers.

TypeDirect peer
Description

VGXI is a specialized plasmid DNA CDMO focused on DNA vaccines and gene therapy applications. Like Touchlight, it provides GMP-grade DNA manufacturing services to biotech and pharma clients developing genetic medicines, with overlapping customer base in DNA vaccines.

TypeBroad incumbent
Description

Catalent is a large incumbent CDMO offering comprehensive biologics, cell therapy, and gene therapy manufacturing services. While it offers plasmid DNA capabilities, its breadth spans oral, injectable, and biologic drug product manufacturing beyond Touchlight's specialized DNA focus.

TypeBroad incumbent
Description

Lonza is both a Touchlight partner (integrating dbDNA into its mRNA offering) and a broad incumbent CDMO. It provides mammalian and microbial biologics manufacturing globally with significantly larger scale and broader service portfolio than Touchlight's focused DNA manufacturing niche.

TypeBroad incumbent
Description

Charles River provides CDMO services including plasmid DNA manufacturing for gene and cell therapy developers via its Biologics Services division. It is a broader preclinical and manufacturing services provider that overlaps with Touchlight in DNA manufacturing for genetic medicines.

TypeDirect peer
Description

GenScript is a direct competitor offering gene synthesis, plasmid DNA, and cell therapy manufacturing services. It serves similar biotech and pharma customers with DNA production and gene editing tools, including custom DNA constructs and viral vector services.

TypeBroad incumbent
Description

Bio-Techne provides research reagents and GMP proteins, with an emerging GMP DNA and gene synthesis capability. While broader in scope (proteins, antibodies, diagnostics), it overlaps with Touchlight in supplying research and GMP-grade materials to genetic medicine developers.

TypeEmerging player
Description

Ansa Bio is an emerging player developing enzymatic DNA synthesis technology for genetic medicines, overlapping with Touchlight's cell-free dbDNA platform. It is an early-stage competitor focused on next-generation synthetic DNA manufacturing for mRNA and gene therapy applications.

TypeBroad incumbent
Description

Oxford Biomedica is a leading lentiviral vector CDMO for cell and gene therapy, recognized as a leading European CGT manufacturer alongside Touchlight. While focused on lentiviral vector production rather than starting DNA, it serves the same gene therapy developer customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Touchlight Genetics

Contract DNA Manufacturingtouchlight.com

Touchlight Genetics is a UK-based CDMO operating a proprietary cell-free enzymatic DNA manufacturing platform (dbDNA) that supplies GMP-grade synthetic DNA to biotech and pharmaceutical companies developing mRNA vaccines, viral vectors, gene editing therapies, and DNA vaccines.

What Touchlight Genetics does

Touchlight Genetics is a UK-based contract development and manufacturing organization (CDMO) that has built a proprietary cell-free DNA production platform to serve the genetic medicines industry. Founded in 2007 and headquartered in Hampton (London), the company's core technology uses enzymatic rolling circle amplification to produce dbDNA (doggybone DNA) — a minimal, linear, double-stranded, covalently closed DNA vector — eliminating the bacterial fermentation step required by traditional plasmid DNA (pDNA) manufacture. This approach reduces production timelines from months to 5-6 weeks, removes antibiotic resistance genes and bacterial sequences from the final product, and operates at a fraction of the facility footprint of conventional CDMOs. The portfolio has expanded to include z-dbDNA (optimized for mRNA production) and mbDNA (a circular single-stranded DNA platform for non-viral gene editing).

Touchlight monetizes through three primary revenue streams: (1) tiered custom DNA manufacturing services spanning Discovery (<1mg, RUO), R&D (2.5mg-5g, RUO), SMart GMP (75mg-5g), and full GMP scales; (2) technology licensing to pharmaceutical partners — including Pfizer, GSK, and Voyager — generating upfront payments, development and commercial milestones, and royalties; and (3) catalogue product and kit sales, including the EnClose Cell-free dbDNA Synthesis Kit co-developed with New England Biolabs. Customers span biotech and pharma companies developing mRNA vaccines, AAV and lentiviral vectors, gene editing therapies, DNA vaccines, and non-viral gene therapies. Distribution extends through channel partnerships with Lonza and Curia for mRNA manufacturing integration.

The Morelands facility in Hampton — a converted Victorian waterworks — is the world's largest cell-free DNA manufacturing site, with 15 production suites and capacity of up to 1kg GMP DNA per month. Touchlight holds the first FDA Drug Master File for an enzymatic DNA platform (2022) and the world's first MHRA GMP license for cell-free DNA manufacturing (January 2025). Nine clinical-stage programs and 8+ IND/CTA filings reference dbDNA, with expansion underway into animal health (Ceva partnership, January 2025), aquaculture (Touchlight Aquaculture spin-off, 2020), and defense applications (DSTL/Naval Research biobattery grants).

Touchlight Genetics firmographics

Firmographics
Name
Touchlight Genetics
Legal name
Touchlight Genetics Ltd.
Website
https://touchlight.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
Touchlight Genetics is a UK-based CDMO operating a proprietary cell-free enzymatic DNA manufacturing platform (dbDNA) that supplies GMP-grade synthetic DNA to biotech and pharmaceutical companies developing mRNA vaccines, viral vectors, gene editing therapies, and DNA vaccines.
Ownership category
akta.pro rank

Touchlight Genetics industry classification

Industry
Product category
Contract DNA Manufacturing
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Cell-free DNA manufacturing
  • CDMO services
  • Enzymatic DNA synthesis
  • Genetic medicine manufacturing
  • DNA vaccine production

Where Touchlight Genetics is headquartered

Location

Headquarters

HQ city
Hampton
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Touchlight Genetics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing (CDMO) Services: Touchlight operates as a CDMO providing custom DNA manufacturing services at multiple scales (Discovery, R&D, SMart GMP, GMP) using its proprietary cell-free dbDNA technology. Revenue is earned through service contracts with biotech and pharma clients who require GMP or RUO-grade DNA for their genetic medicine programs. The company supplies DNA as a critical starting material or raw material for mRNA vaccines, viral vectors (AAV, lentivirus), gene therapies, and DNA vaccines. Customers include pharmaceutical companies, biotech firms, and academic institutions.
  2. Technology Licensing: Touchlight licenses its enzymatic DNA technology (dbDNA patent portfolio) to pharmaceutical companies for use in their own manufacturing processes. Licensing agreements include upfront payments, development and commercial milestone payments, and royalties upon commercialisation. Notable licensees include Pfizer (for mRNA vaccines and gene therapies), GSK (for mRNA manufacturing), and Voyager (for capsid discovery platform).
  3. Catalogue Products: Touchlight sells catalogue DNA products including NVGT (CMV/NVGT Reporters), lentivirus, AAV, gene editing HDR templates, and mRNA constructs for research use.
  4. Kit Sales (Collaboration with NEB): Touchlight co-developed and commercialises the EnClose Cell-free dbDNA Synthesis Kit with New England Biolabs (NEB), providing researchers access to Touchlight's enzymatic DNA synthesis technology in kit format for accelerated DNA and RNA therapeutic development.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractDiscovery Scale: RUO grade DNA up to 1mg for early-stage research
OtherMulti-year contractR&D Scale: RUO grade up to 5g for research and development
OtherMulti-year contractSMart GMP Scale: Accelerating GMP readiness (75mg-5g)
OtherMulti-year contractGMP Scale: High-purity GMP DNA manufacturing (75mg-5g)

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Touchlight Genetics product offering

Product offering

Core offering

Touchlight Genetics is a contract development and manufacturing organization (CDMO) that produces high-purity, cell-free DNA using proprietary enzymatic rolling circle amplification (RCA) technology. The company manufactures dbDNA, z-dbDNA, and mbDNA at multiple scales (Discovery, R&D, SMart GMP, and full GMP) for use as starting material in mRNA vaccines, AAV and lentiviral vectors, gene editing, DNA vaccines, and non-viral gene therapies. The company also licenses its enzymatic DNA patent portfolio to major pharmaceutical companies including Pfizer, GSK, and Voyager.

Product overview

Touchlight Genetics is a pioneering CDMO offering cell-free DNA manufacturing technologies for genetic medicines. The company's core technology portfolio consists of three proprietary DNA platforms: dbDNA (doggybone DNA) - the foundational linear double-stranded DNA vector, z-dbDNA - an optimized variant for mRNA production, and mbDNA (MegaBulb DNA) - a circular single-stranded DNA platform for gene editing. These platforms are delivered through tiered manufacturing services spanning Discovery Scale (RUO, <1mg), R&D Scale (RUO, 2.5mg-5g), SMart GMP (75mg-5g), and full GMP Scale manufacturing. The technology supports a broad range of applications including mRNA synthesis, AAV vector production, lentiviral vector manufacturing, gene editing, DNA vaccines, and non-viral gene therapy. Touchlight's enzymatic cell-free manufacturing eliminates traditional bacterial fermentation, enabling faster production timelines, higher purity, and scalability without antibiotic resistance genes.

Differentiator

Problem solved

Functional benefit

Brands

  • dbDNA™ (doggybone DNA): Enzymatically manufactured double-stranded DNA vector technology for genetic medicines including mRNA, AAV, gene editing, and non-viral therapies
  • z-dbDNA™
  • mbDNA™ (MegaBulb DNA)
  • SMart GMP

Quantifiable outcome

  • GMP-grade dbDNA deliverable in 5-6 weeks, vs. months for traditional plasmid DNA manufacturing
  • +6 more outcomes

Companies that use Touchlight Genetics

Customer profile

Named customers14 records

Segments6 records

Ideal customer profiles5 records

Touchlight Genetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Touchlight Genetics partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered minor and core.

  • U.S. Office for Naval Research / UK Defence Science & Technology LaboratoryminorStrategic or Co-development Partner · 17 April 2026Touchlight was awarded a grant extension (second grant) from the U.S. Office for Naval Research and UK Defence Science & Technology Laboratory (DSTL) to further develop DNA-enabled biobatteries, expanding Touchlight's DNA technology applications beyond biomedical uses.
  • SVF VaccinesminorStrategic or Co-development Partner · 17 April 2026Touchlight announced a strategic partnership with SVF Vaccines to progress SVF's innovative Hepatitis B/D vaccine into clinical development using Touchlight's dbDNA technology as the DNA starting material.
  • New England Biolabs (NEB)coreTechnology or Integration · 18 March 2026New England Biolabs and Touchlight collaborated to develop and release the EnClose Cell-free dbDNA Synthesis Kit, enabling rapid, cell-free DNA synthesis for therapeutics development. The kit offers a scalable and regulatory-friendly alternative to traditional plasmid DNA manufacturing, supporting gene and mRNA therapies.
  • Ceva Animal HealthcoreStrategic or Co-development Partner · 16 January 2025Ceva Animal Health (5th largest global animal health company) entered into a broad-ranging agreement with Touchlight for the development and manufacture of new dbDNA vaccines and therapeutics across a wide range of animal health indications. The agreement includes upfront payment, development milestones, and royalties on commercialised products. Dr Ian Thompson leads the collaboration. Stonehaven Transactions acted as strategic adviser to Touchlight.
  • GSKcoreOEM/ Whitelabel/ Licensing Partner · 23 July 2024GSK signed a license agreement for use of Touchlight's enzymatic dbDNA production technology for mRNA manufacturing. The agreement enables GSK access to the technology for rapid production of DNA template as starting material for mRNA-based vaccines, therapeutics, and gene therapies.
  • LenioBiominorStrategic or Co-development Partner · 2 July 2024Touchlight and LenioBio collaborate to accelerate development of protein therapeutics for pandemic response, as part of LenioBio's CEPI grant. Touchlight contributes its enzymatic dbDNA to the collaborative programme.
  • National Physical Laboratory (NPL)minorStrategic or Co-development Partner · 9 May 2024Touchlight Genetics and the UK's National Physical Laboratory (NPL) were jointly awarded a grant to develop a novel gene-length single-stranded genome editing template, advancing the application of Touchlight's DNA technology in precision gene editing.
  • CPI (Centre for Process Innovation)minorStrategic or Co-development Partner · 28 March 2024Touchlight was awarded a tender to supply enzymatic dbDNA to CPI's RNA Centre of Excellence, supporting the development and manufacturing of RNA therapeutics through access to Touchlight's cell-free DNA technology.
  • CuriaminorChannel Partner/ Reseller/ Distributor · 24 July 2023Curia expanded its biologics capabilities with access to Touchlight's doggybone DNA to complement its mRNA manufacturing offering, enabling Curia's customers to access Touchlight's enzymatic DNA technology.
  • 20Med TherapeuticsminorStrategic or Co-development Partner · 18 April 2023Touchlight and 20Med Therapeutics are collaborating to establish a novel vaccination platform combining Touchlight's rapid enzymatic dbDNA with 20Med's bioresponsive polymer nanoparticle technology. Preclinical data has shown strong neutralising antibodies and durable T cell responses. Funded in part by the Bill & Melinda Gates Foundation for pandemic preparedness.
  • Voyager TherapeuticsminorOEM/ Whitelabel/ Licensing Partner · 15 November 2022Voyager Therapeutics signed a license agreement to use Touchlight's DNA technology in Voyager's capsid discovery platform, leveraging dbDNA's rapid, scalable production for AAV capsid development.
  • LonzacoreStrategic or Co-development Partner · 6 September 2022Lonza integrated Touchlight's dbDNA as an additional, differentiated source of DNA raw material within its end-to-end mRNA manufacturing offering. Customers of Lonza's mRNA manufacturing services gain seamless access to Touchlight's enzymatic DNA technology. The collaboration extends Lonza's offering beyond traditional plasmid DNA while enabling Touchlight to reach customers through Lonza's global mRNA manufacturing network.
  • PfizercoreOEM/ Whitelabel/ Licensing Partner · 6 July 2022Pfizer and Touchlight entered into a non-exclusive patent license agreement granting Pfizer worldwide rights to Touchlight's enzymatic dbDNA patent portfolio for use in Pfizer's clinical and commercial manufacture of mRNA-based vaccines, therapeutics, and gene therapies. Touchlight receives an upfront payment, clinical and commercial milestone payments, and royalties upon commercialisation.
  • AskBio (Bayer AG subsidiary)coreStrategic or Co-development Partner · 8 February 2022AskBio and Touchlight restructured their former Touchlight AAV joint venture on 1 February 2022. Both parties benefit from co-exclusive rights to independently supply the AAV market with dbDNA through their respective CDMOs. AskBio owns 100% of the San Sebastian manufacturing site (operated by TAAV) and Touchlight regains co-exclusive rights to manufacture and sell dbDNA for AAV production.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Touchlight Genetics competitors and assessment

Company assessment

Direct peers

  • Aldevron (Danaher): Aldevron is the leading plasmid DNA CDMO serving gene therapy and mRNA developers. It is the closest direct competitor to Touchlight, providing similar custom DNA manufacturing services for AAV, mRNA, and gene editing applications, though via traditional E. coli fermentation.
  • TriLink BioTechnologies (Maravai LifeSciences): TriLink is a direct competitor in nucleic acid manufacturing, producing mRNA, plasmid DNA, and clean cap reagents for vaccine and therapeutic developers. They serve overlapping customers in mRNA and gene therapy manufacturing with comparable CDMO service tiers.
  • VGXI: VGXI is a specialized plasmid DNA CDMO focused on DNA vaccines and gene therapy applications. Like Touchlight, it provides GMP-grade DNA manufacturing services to biotech and pharma clients developing genetic medicines, with overlapping customer base in DNA vaccines.
  • GenScript: GenScript is a direct competitor offering gene synthesis, plasmid DNA, and cell therapy manufacturing services. It serves similar biotech and pharma customers with DNA production and gene editing tools, including custom DNA constructs and viral vector services.

Broad incumbents

  • Catalent: Catalent is a large incumbent CDMO offering comprehensive biologics, cell therapy, and gene therapy manufacturing services. While it offers plasmid DNA capabilities, its breadth spans oral, injectable, and biologic drug product manufacturing beyond Touchlight's specialized DNA focus.
  • Lonza: Lonza is both a Touchlight partner (integrating dbDNA into its mRNA offering) and a broad incumbent CDMO. It provides mammalian and microbial biologics manufacturing globally with significantly larger scale and broader service portfolio than Touchlight's focused DNA manufacturing niche.
  • Charles River Laboratories: Charles River provides CDMO services including plasmid DNA manufacturing for gene and cell therapy developers via its Biologics Services division. It is a broader preclinical and manufacturing services provider that overlaps with Touchlight in DNA manufacturing for genetic medicines.
  • Bio-Techne: Bio-Techne provides research reagents and GMP proteins, with an emerging GMP DNA and gene synthesis capability. While broader in scope (proteins, antibodies, diagnostics), it overlaps with Touchlight in supplying research and GMP-grade materials to genetic medicine developers.
  • Oxford Biomedica: Oxford Biomedica is a leading lentiviral vector CDMO for cell and gene therapy, recognized as a leading European CGT manufacturer alongside Touchlight. While focused on lentiviral vector production rather than starting DNA, it serves the same gene therapy developer customers.

Emerging players

  • Ansa Bio: Ansa Bio is an emerging player developing enzymatic DNA synthesis technology for genetic medicines, overlapping with Touchlight's cell-free dbDNA platform. It is an early-stage competitor focused on next-generation synthetic DNA manufacturing for mRNA and gene therapy applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Touchlight Genetics social profiles

Digital presence

Touchlight Genetics compliance and trust

Trust signal

Compliance5 records

Touchlight Genetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Touchlight Genetics leadership team

Management profile

Number of profiles

Profiles7 records

Touchlight Genetics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Touchlight Genetics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Touchlight Genetics

What does Touchlight Genetics do?

Touchlight Genetics is a contract development and manufacturing organization (CDMO) that produces high-purity, cell-free DNA using proprietary enzymatic rolling circle amplification (RCA) technology. The company manufactures dbDNA, z-dbDNA, and mbDNA at multiple scales (Discovery, R&D, SMart GMP, and full GMP) for use as starting material in mRNA vaccines, AAV and lentiviral vectors, gene editing, DNA vaccines, and non-viral gene therapies. The company also licenses its enzymatic DNA patent portfolio to major pharmaceutical companies including Pfizer, GSK, and Voyager.

Is Touchlight Genetics a public or private company?

Touchlight Genetics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Touchlight Genetics founded?

Touchlight Genetics was founded in 2007. It employs 101 to 250 people.

Where is Touchlight Genetics based?

Touchlight Genetics is headquartered in Hampton, United Kingdom, in the Europe region.

How does Touchlight Genetics make money?

Four revenue lines are on record. Contract Development and Manufacturing (CDMO) Services are the primary driver. The others are technology Licensing, catalogue Products and kit Sales (Collaboration with NEB).

Who are Touchlight Genetics's main competitors?

Direct peers on record are Aldevron (Danaher), TriLink BioTechnologies (Maravai LifeSciences), VGXI and GenScript. Broad incumbents are Catalent, Lonza, Charles River Laboratories, Bio-Techne and Oxford Biomedica. Ansa Bio is listed as an emerging player.

Does Touchlight Genetics have an API?

No public API is recorded for Touchlight Genetics.

What industry is Touchlight Genetics in?

Touchlight Genetics's product category is Contract DNA Manufacturing. Its primary akta.pro industry code is HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO, with a secondary code of HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalTouchlight announces leadership transition, with Will Downie appointed interim CEOKaren Fallen stepped down as CEO of Touchlight, and the board appointed Will Downie as interim CEO. Downie brings over 30 years of CDMO experience, including prior roles at Argenta and Vectura. He will help develop Touchlight's scale and growth in cell and gene therapy.The Pharma LetterWill Downie appointed interim CEO at TouchlightKaren Fallen is stepping down as CEO of Touchlight, and the board has appointed Will Downie as interim CEO. Fallen has served since November 2020 and achieved approval of the world's first GMP-license for the company's synthetic DNA facility in London.BioProcess InternationalFallen in place: Lonza veteran to lead TouchlightTouchlight has appointed Karen Fallen, formerly of Lonza, as the CEO of its contract manufacturing arm, Touchlight DNA Services. The company aims to expand its client base and address production bottlenecks for synthetic DNA, which is critical for mRNA vaccines and advanced therapies. This strategic move supports Touchlight's broader efforts in the growing cell and gene therapy market amid rising demand.BioProcess InternationalDoggybone DNA ‘ideal tech’ for pandemic vaccineTouchlight has developed doggybone DNA (dbDNA), a new vector technology designed to overcome the manufacturing and stability limitations of existing plasmid DNA and mRNA vaccines. The company reports that dbDNA is 10-100 times more potent than traditional pDNA in inducing immune responses while allowing for faster, simpler manufacturing processes suitable for global distribution. This technology enables rapid production of vaccine material within weeks, offering potential advantages for responding to emerging variants like Omicron.Mirage NewsPatient Gets World's First Lung Cancer VaccineResearchers and clinicians from the University of Liverpool and Clatterbridge Cancer Centre have administered the world's first personalized lung cancer vaccine to a patient, Chris Jones, as part of the NEOVACC Phase I clinical trial targeting advanced non-small cell lung cancer. The vaccine uses innovative 'doggybone DNA' technology from Touchlight and computational tumor-targeting tools from myNEO to create a bespoke treatment designed to boost the immune system's ability to recognize and attack tumor cells. The trial, funded by a £2.66m grant from the Medical Research Council, will assess safety and immune response in 10 participants, with potential to benefit over half of advanced lung cancer patients.The Pharma LetterTouchlight links up with SVF Vaccines to advance hepatitis B/D vaccineTouchlight, a UK biotechnology company, partnered with SVF Vaccines to advance the company's hepatitis B/D vaccine into clinical development. The collaboration uses Touchlight's doggybone DNA platform, which offers dose-sparing advantages over traditional plasmid DNA.PharmiWeb.comTouchlight and New England Biolabs® Unveil EnClose™ Cell-free dbDNA™ Synthesis Kit to Accelerate Next Generation DNA and RNA Therapeutic DevelopmentTouchlight and New England Biolabs announced the launch of the EnClose™ Cell-free dbDNA™ Synthesis Kit, a benchtop solution enabling rapid enzymatic production of doggybone DNA (dbDNA™). The kit offers a cell-free alternative to traditional plasmid DNA manufacturing, allowing researchers to bypass complex bacterial fermentation processes and generate high-purity DNA templates in a single day. This collaboration combines Touchlight's proprietary dbDNA platform with NEB's enzymatic expertise to accelerate the development timeline for mRNA vaccines, gene therapies, and other nucleic acid therapeutics.ScienceNew ProductsThe article presents a collection of corporate announcements from the biotechnology and life sciences sector, detailing new product launches and technological milestones. Key developments include Touchlight's use of its dbDNA technology in U.S. clinical studies, 4basebio's launch of a rebranded website following significant investment, and Revvity's release of new IVD reference standards for cancer testing. Additionally, Bio-Rad expanded its digital PCR portfolio through the acquisition of Stilla Technologies.InsidermediaB P Collins advises Ceva Animal Health on deal with TouchlightCeva Animal Health has entered into a partnership with Touchlight to utilize its dbDNA technology for developing new animal health therapeutics. The agreement includes upfront payments, development milestones, and royalties on sales of commercialized products. This collaboration aims to combine Ceva's vaccine expertise with Touchlight's synthetic DNA capabilities to bring innovative genetic medicine vaccines to market.PharmiWeb.comTouchlight’s dbDNA™ Manufacturing Facility Receives World-First GMP License from MHRATouchlight's Hampton, UK facility received an MHRA GMP license to produce Active Pharmaceutical Ingredients from synthetic DNA, making it the first synthetic DNA manufacturer globally to gain such approval. The facility, completed in 2023, has a capacity of over 8kg per year, exceeding current global DNA supply. Touchlight has begun manufacturing API material under the license.